Clinical trial NCT01216449: Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Official title: Pharmacodynamics of Intravenous Citalopram in the Elderly: a Functional Magnetic Resonance Imaging Analysis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Healthy Young and Elderly Volunteers
Keywords: Citalopram
Functional Magnetic Resonance Imaging
fMRI
Pharmacokinetics
Pharmacodynamics
Amygdala
Elderly
Lead sponsor: Rotman Research Institute at Baycrest
Sponsor class: OTHER
Collaborators: name: Centre for Addiction and Mental Health
name: University of Toronto
First posted: 2010-10-07
Enrollment: 29
Sex: MALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs) are most commonly prescribed to treat depression and anxiety. How antidepressants work on the brain to alter mood and behaviour is not well understood. This study will use a brain scanning technique (functional magnetic resonance imaging) to examine how aging impacts brain activation during emotional tasks after the administration of intravenous (IV) citalopram (this is the only SSRI available in this form, and is well tolerated and safe in young and old adults). The investigators will further determine what role genetic differences play in this relationship. The investigators expect to see an increase in brain signal as the concentration of IV citalopram increases. However, the investigators propose that the brain signal in older adults will not be as strong as in younger adults. Furthermore, the investigators expect that participants genetically predisposed to have fewer serotonin transporters (the site of action of SSRIs) will show greater decreases in brain activation with citalopram.


Eligibility criteria: Inclusion Criteria:

* Male aged 60 or older (elderly group)
* Male aged 20-40 (younger adult group)
* English speaking
* Right-handed
* Non-smoker
* Score of 27 or greater on the Mini Mental State Exam

Exclusion Criteria:

* Unstable medical, cardiac, or neurological illness (including stroke, brain tumour, epilepsy, significant head injury, Alzheimer's, Parkinson's or Huntington's disease)
* Laboratory results indicating unanticipated illness or intolerability of blood drawing procedures or of study drug
* Current or lifetime Axis-I psychiatric diagnosis on the DSM-IV/SCID (i.e., Module A: Mood, Module F: Anxiety, Module B \& C: Psychosis)
* History of drug or alcohol abuse within one year, or lifetime history of alcohol or drug dependence (i.e., SCID Module E: Substance Abuse, or clinically significant urine toxicology screen)
* History of non-tolerance to SSRI therapy; including history of SSRI-related syndrome of inappropriate antidiuretic hormone secretion (SIADH) or sinus bradycardia on ECG (less than 50 beats per minute)
* Contraindication to MRI (as per MRI Contraindication Screening Form)

Primary outcomes:
measure: BOLD fMRI Response
timeFrame: Visit 1, Visit 2
Secondary outcomes:
measure: Genetics and Cognitive/Emotional Change
timeFrame: Visit 1, Visit 2
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Rotman Research Institute at Baycrest
state: Ontario
Study officials:
affiliation: Centre for Addiction and Mental Health
name: Bruce G Pollock, MD PhD FRCPC
role: PRINCIPAL_INVESTIGATOR
References: